loan agreement
Bluebird Bio Enters Into $175M Loan Deal
The firm can borrow the funds over four tranches and use it to market its FDA-approved gene therapies including the sickle cell therapy Lyfgenia.
Elevation Oncology Licenses ADC-Targeting Claudin18.2 for Development in Solid Tumors
Elevation is acquiring global rights to develop EO-3021 outside of China for $27 million upfront, supported by a $50 million loan from K2 HealthVentures.